MDEA盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: MDEA盐酸盐
• 中文别名: 1-(1,3-苯并二氧戊环-5-基)-N-乙基丙-2-胺盐酸盐；MDEA 盐酸盐
• 英文名称: 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine;hydron;chloride
• 化学式: C12H18ClNO2
• 分子量: 243.73
• InChiKey: IBDIPBWIXJRJQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Test kit for the quantitative determination of narcotic drugs
  申请人：Chiron AS

  公开号：EP2687854A1

  公开（公告）日：2014-01-22

  A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, - wherein the isotopologue differs from vessel to vessel and - wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; - wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13C, 15N and 18O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.

  用于定量测定麻醉药品的试剂盒，包括 (A) 一系列密封容器，每个容器装有浓度和数量完全确定的麻醉药品的无 氘同位素、 - 其中各容器的同位素不同，并且 - 其中同位素的数量因容器而异或所有容器相同；和/或 (B) 一系列密封容器，每个容器以完全确定的浓度和数量含有相同的同位 素，其数量因容器而异； - 其中游离的同位素选自麻醉药品；原药、盐、溶液、水合物和多晶型物，以及 分子中至少含有三个稳定同位素，选自 13C、15N 和 18O 组成的组，标记度至少为 95 摩尔-%； 使用检测试剂盒和方法定量测定麻醉药品。
• TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS
  申请人：Chiron AS

  公开号：EP2875362A1

  公开（公告）日：2015-05-27
• Antiparkinsonian Action of Phenylisopropylamines
  申请人：Caron G. Marc

  公开号：US20070027208A1

  公开（公告）日：2007-02-01

  A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
• US8877802B2
  申请人：——

  公开号：US8877802B2

  公开（公告）日：2014-11-04
• [EN] ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES<br/>[FR] ACTION ANTIPARKINSONIENNE DE PHENYLISOPROPYLAMINES
  申请人：UNIV DUKE

  公开号：WO2007016190A2

  公开（公告）日：2007-02-08

  [EN] A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
  [FR] L'invention concerne une méthode pour traiter un patient présentant la maladie de Parkinson. Cette méthode consiste à administrer à ce patient une phénylisopropylamine dans une quantité efficace pour traiter ladite maladie de Parkinson. Dans certains modes de réalisation, la méthode est utilisée pour traiter au moins un symptôme moteur de la maladie de Parkinson. Dans d'autres modes de réalisation de la méthode de l'invention, cette méthode est utilisée pour traiter au moins un symptôme non moteur de la maladie de Parkinson.